| Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes B Zinman, C Wanner, JM Lachin, D Fitchett, E Bluhmki, ... New England Journal of Medicine 373 (22), 2117-2128, 2015 | 13270 | 2015 |
| Empagliflozin and progression of kidney dsease in type 2 diabetes C Wanner, SE Inzucchi, JM Lachin, D Fitchett, M von Eynatten, ... New england journal of medicine 375 (4), 323-334, 2016 | 3830 | 2016 |
| Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome G Marchesini, E Bugianesi, G Forlani, F Cerrelli, M Lenzi, R Manini, ... Hepatology 37 (4), 917-923, 2003 | 3686 | 2003 |
| The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ... Hepatology 45 (4), 846-854, 2007 | 3608 | 2007 |
| Nonalcoholic fatty liver disease: a feature of the metabolic syndrome G Marchesini, M Brizi, G Bianchi, S Tomassetti, E Bugianesi, M Lenzi, ... Diabetes 50 (8), 1844-1850, 2001 | 3449 | 2001 |
| EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease G Marchesini, CP Day, JF Dufour, A Canbay, V Nobili, V Ratziu, H Tilg, ... Journal of Hepatology 64 (6), 1388-1402, 2016 | 2689* | 2016 |
| EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease EA the Study of the Liver (EASL), EA the Study of Diabetes (EASD), ... Journal of Hepatology 64 (6), 1388-1402, 2016 | 2678* | 2016 |
| EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease European Association for The Study of The Liver, ... Obesity facts 9 (2), 65-90, 2016 | 2678 | 2016 |
| A randomized, controlled trial of 3.0 mg of liraglutide in weight management X Pi‑Sunyer, A Astrup, K Fujioka, F Greenway, A Halpern, M Krempf, ... New England Journal of Medicine 373 (1), 11-22, 2015 | 2331 | 2015 |
| Association of nonalcoholic fatty liver disease with insulin resistance G Marchesini, M Brizi, AM Morselli-Labate, G Bianchi, E Bugianesi, ... The American journal of medicine 107 (5), 450-455, 1999 | 2265 | 1999 |
| Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma E Bugianesi, N Leone, E Vanni, G Marchesini, F Brunello, P Carucci, ... Gastroenterology 123 (1), 134-140, 2002 | 1895 | 2002 |
| Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study G Bedogni, L Miglioli, F Masutti, C Tiribelli, G Marchesini, S Bellentani Hepatology 42 (1), 44-52, 2005 | 1885 | 2005 |
| Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ... Journal of hepatology 69 (4), 896-904, 2018 | 1710 | 2018 |
| A position statement on NAFLD/NASH based on the EASL 2009 special conference V Ratziu, S Bellentani, H Cortez-Pinto, C Day, G Marchesini Journal of hepatology 53 (2), 372-384, 2010 | 1474 | 2010 |
| Insulin resistance: a metabolic pathway to chronic liver disease E Bugianesi, AJ McCullough, G Marchesini Hepatology 42 (5), 987-1000, 2005 | 1173 | 2005 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1131 | 2019 |
| Metformin in non-alcoholic steatohepatitis G Marchesini, G Bianchi, S Tomassetti, M Zoli, N Melchionda The Lancet 358 (9285), 893-894, 2001 | 1104 | 2001 |
| Clinical features and natural history of nonalcoholic steatosis syndromes Y Falck-Ytter, ZM Younossi, G Marchesini, AJ McCullough Seminars in liver disease 21 (01), 017-026, 2001 | 1041 | 2001 |
| A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease E Bugianesi, E Gentilcore, R Manini, S Natale, E Vanni, N Villanova, ... The American journal of gastroenterology 100 (5), 1082, 2005 | 1027 | 2005 |
| Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes AL Fracanzani, L Valenti, E Bugianesi, M Andreoletti, A Colli, E Vanni, ... Hepatology 48 (3), 792-798, 2008 | 894 | 2008 |
Giampaolo BianchiUniversitą di BolognaVerified email at unibo.it
